IVERIC bio - ISEE Stock Forecast, Price & News

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Analyst Ratings Changes

Several research firms have commented on ISEE. Guggenheim started coverage on shares of IVERIC bio in a research note on Wednesday, June 8th. They set a "buy" rating and a $30.00 price objective for the company. UBS Group assumed coverage on IVERIC bio in a research note on Tuesday, August 2nd. They issued a "buy" rating and a $20.00 price objective for the company. Stifel Nicolaus boosted their target price on IVERIC bio from $22.00 to $28.00 in a report on Wednesday, May 4th. Morgan Stanley boosted their target price on IVERIC bio from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, July 7th. Finally, B. Riley initiated coverage on IVERIC bio in a research note on Thursday, May 12th. They set a "neutral" rating and a $12.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $24.20.

IVERIC bio Stock Performance

NASDAQ:ISEE opened at $13.38 on Wednesday. The firm has a 50-day simple moving average of $10.75 and a two-hundred day simple moving average of $13.20. The firm has a market cap of $1.58 billion, a P/E ratio of -10.97 and a beta of 1.52. IVERIC bio has a fifty-two week low of $8.37 and a fifty-two week high of $19.34.

IVERIC bio (NASDAQ:ISEE - Get Rating) last issued its quarterly earnings results on Tuesday, July 26th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter last year, the firm earned ($0.32) EPS. On average, equities research analysts predict that IVERIC bio will post -1.49 EPS for the current year.

Insider Activity

In other IVERIC bio news, Director Calvin W. Roberts acquired 25,000 shares of the stock in a transaction that occurred on Monday, June 13th. The stock was bought at an average cost of $9.62 per share, with a total value of $240,500.00. Following the completion of the purchase, the director now directly owns 32,500 shares in the company, valued at $312,650. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Calvin W. Roberts bought 25,000 shares of IVERIC bio stock in a transaction on Monday, June 13th. The stock was acquired at an average cost of $9.62 per share, for a total transaction of $240,500.00. Following the completion of the acquisition, the director now owns 32,500 shares of the company's stock, valued at approximately $312,650. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christopher Paul Simms sold 12,272 shares of the business's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $11.25, for a total transaction of $138,060.00. Following the completion of the transaction, the senior vice president now owns 28,547 shares of the company's stock, valued at $321,153.75. The disclosure for this sale can be found here. Insiders own 2.70% of the company's stock.